ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler: One-Off Effects and Robust Operating Business Push Nine-Month Result to Record Level

11/09/2021 | 01:47am EDT

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figures
Eckert & Ziegler: One-Off Effects and Robust Operating Business Push Nine-Month Result to Record Level

09.11.2021 / 07:45
The issuer is solely responsible for the content of this announcement.


Berlin, 9 November 2021. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a record result in the first nine months of 2021 with a net profit of ? 29.2 million or ? 1.41 per share. By the end of September, earnings had thus already exceeded those of the entire previous year by ? 11.6 million or 65%. Adjusted for the tumor irradiation business, which has been sold in the meantime, Group sales totaled ? 126 million, up ? 9 million or 8% on the previous year's level.

Although a large part of the 2021 earnings growth resulted from the sale of the tumor device business, the development of the operating business in both segments was also extremely encouraging. Adjusted for one-off effects of ? 9.1 million, earnings before interest and taxes (EBIT) in the Medical segment rose by 28% from ? 15.6 million to ? 19.9 million. In the Isotope Products segment, EBIT increased even more by 44% from ? 7.7 million to ? 11.1 million. In this segment, the return to the pre-Corona earnings level has stabilized. The holding company closed the nine-month period with EBIT of ? 0.3 million. In total, the segment earnings added up to a Group EBIT of more than ? 40 million.

The Medical segment was able to increase its sales revenues by ? 6.7 million or 14%, adjusted for the revenues from the tumor irradiation business, which was still included in the previous year and has since been sold. Sales to pharmaceutical companies developed dynamically, with orders for services and products relating to radiopharmaceuticals and pharmaceutical radioisotopes up by around 16%. Sales of laboratory equipment, brachytherapy and other products and services increased by 9%.

The Isotope Products segment generated sales of ? 73.1 million, around 5% higher than in the first nine months of 2020. Net profit rose by almost 55%. Following the slumps in connection with the COVID pandemic last year, the segment was thus able to return to the growth path as expected.

Based on the nine-month figures, the Executive Board continues to confirm the previously issued sales and earnings guidance of approximately ? 180 million, or around ? 1.70 per share.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz321e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



09.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1247197

 
End of News DGAP News Service

1247197  09.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1247197&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 216 M 216 M
Net income 2022 30,7 M 32,3 M 32,3 M
Net cash 2022 55,7 M 58,7 M 58,7 M
P/E ratio 2022 28,8x
Yield 2022 1,17%
Capitalization 890 M 938 M 938 M
EV / Sales 2022 4,07x
EV / Sales 2023 3,91x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 42,90 €
Average target price 152,00 €
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-54.41%938
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868